Over the past decade, pharma’s interaction with digital health has grown more sophisticated and purposeful. In the last year however, innovation wrapped around the drug has become the object of budgetary scrutiny in pharmaceutical companies. So why continue to invest in digital health?

There was a wide range of topics discussed at our HealthXL meetings this February. To make sure you’re not missing out on the insightful discussions between community members and to keep you plugged into the conversation, here are Tess' five meeting takeaways from the past month.